Results 51 to 60 of about 1,226,593 (337)

Clathrin structure characterized with monoclonal antibodies. I. Analysis of multiple antigenic sites. [PDF]

, 1985
Three monoclonal antibodies that react with previously undefined antigenic determinants on the clathrin molecule have been produced and characterized. They were isolated from a fusion between myeloma cells and popliteal lymphocytes from SJL mice that had
Brodsky, Frances
core  

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Antitumor activity of an anti-CD98 antibody. [PDF]

, 2015
CD98 is expressed on several tissue types and specifically upregulated on fast-cycling cells undergoing clonal expansion. Various solid (e.g., nonsmall cell lung carcinoma) as well as hematological malignancies (e.g., acute myeloid leukemia) overexpress ...
Cairns, Belinda, Cantor, Joseph M, Chinn, Lawrence, Duey, Dana, Ginsberg, Mark H, H van der Horst, Edward, Hayes, Gregory M, Levashova, Zoia, Lippincott, John, Tran, Hoang, Velilla, Timothy, Zachwieja, Joseph   +11 more
core   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice [PDF]

Iranian Journal of Immunology, 2017
Background: In addition to passive immunotherapy using anti-HER2 monoclonal antibodies, active immunotherapy via HER2 targeting is an interesting approach to inducing specific anti-tumor immune responses.
Fateme Sadri-Ardalani, Moslem Ahmadi, Azam Hemmati, Shaghayegh Emami, Samira Farid, Mohammad Mehdi Amiri, Mahmood Jeddi-Tehrani, Mahdi Shabani, Fazel Shokri   +8 more
doaj  

Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2

Communications Biology, 2021
Song et al describe and identify monoclonal antibodies that target the SARSCoV-2 Spike protein, including CA521FALA, which demonstrated neutralising potential in vivo and in vitro.
Deyong Song, Wenbo Wang, Chuangchuang Dong, Zhenfei Ning, Xiu Liu, Chuan Liu, Guangying Du, Chunjie Sha, Kailin Wang, Jun Lu, Baiping Sun, Yanyan Zhao, Qiaoping Wang, Hongguang Xu, Ying Li, Zhenduo Shen, Jie Jiao, Ruiying Wang, Jingwei Tian, Wanhui Liu, Lan Wang, Yong-Qiang Deng, Changlin Dou   +22 more
doaj   +1 more source

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]

, 2018
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim, Crosetti, Anna M, Cummings, Amy L, Drakaki, Alexandra, Faiena, Izak, Pantuck, Allan J   +5 more
core   +1 more source

Monoclonal antibodies against human astrocytomas and their reactivity pattern [PDF]

, 1987
The establishment of hybridomas after fusion of X63-Ag8.653 mouse myeloma cells and splenocytes from mice hyperimmunized against human astrocytomas is presented. The animals were primed with 5 × 106 chemically modified uncultured or cultured glioma cells.
B. Martin, Bourdon, Bullard, Bullard, Carrel, Coakham, Coakham, D. Stavrou, De Muralt, E. Keiditsch, Epenetos, F. Schmidberger, I. Funke, Jonak, K. Bise, Kearney, Kemshead, Krajewski, Köhler, Lanier, Posner, R. Kurrle, Roholl, Schnegg, Seeger, Sikora, Stavrou, Stavrou, Stavrou, Stavrou, Stavrou, Stavrou, Stavrou, Taub, U. Stocker, W. Eisenmenger, Wikstrand   +36 more
core   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5

Cell Discovery, 2023
SARS-CoV-2 Omicron subvariants have demonstrated extensive evasion from monoclonal antibodies (mAbs) developed for clinical use, which raises an urgent need to develop new broad-spectrum mAbs.
Yanqun Wang, An Yan, Deyong Song, Chuangchuang Dong, Muding Rao, Yuanzhu Gao, Ruxi Qi, Xiaomin Ma, Qiaoping Wang, Hongguang Xu, Hong Liu, Jing Han, Maoqin Duan, Shuo Liu, Xiaoping Yu, Mengqi Zong, Jianxia Feng, Jie Jiao, Huimin Zhang, Min Li, Beibei Yu, Yanxia Wang, Fanhao Meng, Xiaodan Ni, Ying Li, Zhenduo Shen, Baiping Sun, Xin Shao, Haifeng Zhao, Yanyan Zhao, Rui Li, Yanan Zhang, Guangying Du, Jun Lu, Chunna You, Hua Jiang, Lu Zhang, Lan Wang, Changlin Dou, Zheng Liu, Jincun Zhao   +40 more
doaj   +1 more source